Presentation Information
[O1-04]Delandistrogene moxeparvovec投与後のDMD患者における急性肝障害の軽減と管理:エキスパートの見解
小牧 宏文1, Shieh Perry2, Diamond Tamir3, Chapin Catherine A.4, Ahmad Jawad5, Salama Alan6, Soslow Jonathan7, Veerapandiyan Aravindhan8, Gerber Marianne9, Asher Damon10 (1.国立精神・神経医療研究センタートランスレーショナル・メディカルセンター, 2.University of California Los Angeles, Los Angeles, CA, USA, 3.Children's Hospital of Philadelphia, Philadelphia, PA, USA, 4.Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA, 5.Mount Sinai, New York, NY, USA, 6.University College, London, UK, 7.Vanderbilt University Medical Center, Nashville, TN, USA, 8.Arkansas Children's Hospital, Little Rock, AR, USA, 9.F. Hoffmann-La Roche Ltd, Basel, Switzerland, 10.Sarepta Therapeutics, Inc., Cambridge, MA, USA)
Password required to view
Comment
To browse or post comments, you must log in.Log in
